Trial · NCT07905599
Molecular Evidence of Rejection Intervention Trial
NCT07905599, Not applicable, Not yet recruiting, CareDx
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Molecular Evidence of Rejection Intervention Trial. Trials, record NCT07905599. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07905599
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Molecular Evidence of Rejection Intervention Trial
- NCT number
- NCT07905599
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 200 participants, estimated
- Lead sponsor
- CareDx
- Conditions
- Heart Transplant Rejection
- Interventions
- Prednisone, Placebo
- First posted
- 2026-10-29
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Primary Endpoint | Assessed at 180 (± 14) days post-randomization | A hierarchical composite outcome of time to death or re-transplantation, time to graft dysfunction (LVEF \<50%), time to ACR 2R higher and/or pAMR1 or higher, hospitalization (yes/no), dd-cfDNA \<0.20% (yes/no), and percent reduction in dd-cfDNA from randomization. |
| Secondary | Secondary Endpoint | Assessed at 28 (±7) days post-randomization | A hierarchical composite outcome of time to death or re-transplantation, time to graft dysfunction (LVEF \<50%), time to ACR 2R higher and/or pAMR1 or higher, hospitalization (yes/no), dd-cfDNA \<0.20% (yes/no), and percent reduction in dd-cfDNA from randomization. |
| Secondary | Safety Endpoint | Randomization through study completion, an average of 1 year. | Incidence of infection requiring treatment with antibiotics, antivirals, and/or antifungals, hyperglycemia requiring an unplanned clinic visit, emergency room visit or hospitalization, and bone fracture or avascular necrosis. |
| Other | 6 Month Exploratory Endpoint | Assessed at 180 (± 14) days post-randomization | Evaluate additional biomarkers including DSA and Teno torque virus (TTV) levels; presence of ≥1 de novo DSA. |
| Other | 12 Month Exploratory Endpoint | Assessed at 365 (±30) days post-randomization | A hierarchical composite outcome of time to death or re-transplantation, time to graft dysfunction (LVEF \<50%), time to ACR 2R higher and/or pAMR1 or higher, hospitalization (yes/no), dd-cfDNA \<0.20% (yes/no), and percent reduction in dd-cfDNA from randomization. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers13
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07905599
GET https://conductscience.org/api/trials/v1/NCT07905599/registered